Literature DB >> 19572947

Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study.

R Rusina1, P Ridzon, P Kulist'ák, O Keller, A Bartos, M Buncová, L Fialová, F Koukolík, R Matej.   

Abstract

INTRODUCTION: Amyotrophic lateral sclerosis (ALS) is a common neurodegenerative disease affecting motor neurons and may be associated with impaired cognition. Reliable prognostic factors for ALS patients are still missing.
METHODS: We prospectively included 67 patients, 42 women and 25 men, with clinically defined ALS. The disease severity was assessed and the patients underwent SPECT, lumbar puncture with determination of tau, hyperphosporylated tau (p-tau) and beta-amyloid and a detailed neuropsychological assessment using a standardized test battery. In patients who died, a detailed neuropathologic evaluation was performed.
RESULTS: The mean survival duration was 26.8 months. The delay between the first signs and confirmation of the diagnosis was 12.75 months. Cognitive impairment did not have an impact on the evolution of the disease. There was no correlation between neuropsychological and SPECT findings. Higher age at onset, more pronounced handicap and elevated beta-amyloid in the CSF were associated with shorter survival times. In brain tissue from nine of the deceased patients with ALS and dementia, all showed signs of comorbidity, six had hallmarks of frontotemporal lobar degeneration (FTLD) and three showed Alzheimer disease pathology. Brain tissues form 11 deceased ALS patients who did not show signs of dementia, had only changes compatible with a diagnosis of motor neuron disease.
CONCLUSION: In our prospective study, age, disease severity and CSF beta-amyloid levels taken together were a risk factor suggesting shorter survival times. Dementia is relatively frequent in ALS and may be a consequence of either FTLD or result from co-existing Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19572947     DOI: 10.1111/j.1468-1331.2009.02717.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  24 in total

Review 1.  Comorbidities in Neurology: Is adenosine the common link?

Authors:  Detlev Boison; Eleonora Aronica
Journal:  Neuropharmacology       Date:  2015-05-13       Impact factor: 5.250

2.  Trail Making Test error analysis in classic motor neuron disease.

Authors:  Foteini Christidi; Evangelia Kararizou; Nikolaos I Triantafyllou; George P Paraskevas; Ioannis Zalonis
Journal:  Neurol Sci       Date:  2012-11-18       Impact factor: 3.307

3.  Comorbidity of dementia with amyotrophic lateral sclerosis (ALS): insights from a large multicenter Italian cohort.

Authors:  Francesca Trojsi; Mattia Siciliano; Cinzia Femiano; Gabriella Santangelo; Christian Lunetta; Andrea Calvo; Cristina Moglia; Kalliopi Marinou; Nicola Ticozzi; Gianluca Drago Ferrante; Carlo Scialò; Gianni Sorarù; Amelia Conte; Yuri M Falzone; Rosanna Tortelli; Massimo Russo; Valeria Ada Sansone; Adriano Chiò; Gabriele Mora; Barbara Poletti; Paolo Volanti; Claudia Caponnetto; Giorgia Querin; Mario Sabatelli; Nilo Riva; Giancarlo Logroscino; Sonia Messina; Antonio Fasano; Maria Rosaria Monsurrò; Gioacchino Tedeschi; Jessica Mandrioli
Journal:  J Neurol       Date:  2017-09-15       Impact factor: 4.849

Review 4.  Clinical phenomenology and neuroimaging correlates in ALS-FTD.

Authors:  Catherine Lomen-Hoerth
Journal:  J Mol Neurosci       Date:  2011-10-05       Impact factor: 3.444

5.  Quantitative brain MR imaging in amyotrophic lateral sclerosis.

Authors:  Jiří Keller; Josef Vymazal; Petr Ridzoň; Robert Rusina; Petr Kulišt'ák; Hana Malíková; Aaron M Rulseh; Otakar Keller; Robert Jech
Journal:  MAGMA       Date:  2011-03-15       Impact factor: 2.310

6.  Use of fuzzy edge single-photon emission computed tomography analysis in definite Alzheimer's disease--a retrospective study.

Authors:  Robert Rusina; Jaromír Kukal; Tomás Belícek; Marie Buncová; Radoslav Matej
Journal:  BMC Med Imaging       Date:  2010-09-01       Impact factor: 1.930

Review 7.  Adenosine kinase: exploitation for therapeutic gain.

Authors:  Detlev Boison
Journal:  Pharmacol Rev       Date:  2013-04-16       Impact factor: 25.468

8.  Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis.

Authors:  Murray Grossman; Lauren Elman; Leo McCluskey; Corey T McMillan; Ashley Boller; John Powers; Katya Rascovsky; William Hu; Les Shaw; David J Irwin; Virginia M-Y Lee; John Q Trojanowski
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

9.  Self-Regulation and Executive Functioning as Related to Survival in Motor Neuron Disease: Preliminary Findings.

Authors:  Natasha E Garcia-Willingham; Abbey R Roach; Edward J Kasarskis; Suzanne C Segerstrom
Journal:  Psychosom Med       Date:  2018-09       Impact factor: 4.312

10.  Behavior matters--cognitive predictors of survival in amyotrophic lateral sclerosis.

Authors:  William T Hu; Matthew Shelnutt; Ashley Wilson; Nicole Yarab; Crystal Kelly; Murray Grossman; David J Libon; Jaffar Khan; James J Lah; Allan I Levey; Jonathan Glass
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.